ALLO — Allogene Therapeutics Balance Sheet

0.000.00%

Last trade - 00:00

HealthcareAdventurousSmall CapNeutral

Annual balance sheet for Allogene Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	R2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	—	—	—	—	—
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Cash and Equivalents
Short Term Investments
Cash and Short Term Investments	828	457	517	449	292
Net Total Accounts Receivable
Net Total Receivables	2.8	1.9	1.8	1.7	1.9
Prepaid Expenses
Total Current Assets	845	471	529	459	303
Gross Property, Plant And Equipment
Accumulated Depreciation
Net Property, Plant And Equipment	160	181	196	163	131
Net Intangible Assets
Long Term Investments
Other Long Term Assets
Total Assets	1,228	1,039	822	643	549
Accounts Payable
Accrued Expenses
Notes Payable / Short Term Debt
Total Other Current Liabilities
Total Current Liabilities	94.3	48.2	53.7	37.1	35.5
Total Long Term Debt
Total Debt
Total Other Liabilities
Total Liabilities	148	122	155	131	127
Non Redeemable Preferred Stock
Common Stock
Additional Paid In Capital
Retained Earnings (Accumulated Deficit)
Other Equity
Total Equity	1,080	916	667	512	422
Total Liabilities & Shareholders' Equity	1,228	1,039	822	643	549
Total Common Shares Outstanding